RxDoctor Payments Data

Kassra Poosti, MD

Interventional Cardiology · West Hills, CANPI 1174918536

Payments from drug & device makers

$1,385in general payments, 2019–2025

Across 58 payments — averaging $23.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$159
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$148
  • Amgen$144
  • Medtronic$143
  • Merck$121
  • Novo Nordisk$97
  • plus $573 from 11 others

What the payments were for

  • Grants$554%
  • Food & beverage$1,33096%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,385 in reported general payments places this provider in the 15th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$1,657
Medicare patients
25
Services billed
40

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PradaxaDabigatran Etexilate Mesylate301$85,708
JardianceEmpagliflozin145$70,002
EliquisApixaban46$56,168
EntrestoSacubitril/Valsartan17$15,987
Dabigatran EtexilateDabigatran Etexilate Mesylate38$7,384
Metoprolol Tartrate249$2,744
Atorvastatin Calcium203$2,651
Bisoprolol Fumarate114$2,508
ClopidogrelClopidogrel Bisulfate108$2,012
Amlodipine Besylate157$1,923
Diltiazem 24hr Er (Cd)Diltiazem Hcl53$1,810
Cartia XtDiltiazem Hcl40$1,785
Rosuvastatin Calcium130$1,503
Losartan Potassium116$1,373
Carvedilol116$1,369

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimPradaxa, Jardiance$77$155,710446 claims
PfizerEliquis$159$56,16846 claims
NovartisEntresto$61$15,98717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in West Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →